Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral contraceptives versus expectant management for retained products of conception after abortion
IRCT20260516069413N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of ethinylestradiol + levonorgestrel and doxycycline in Incomplete Abortion (IA) and retained placenta (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Retained products of conception. Started Jun 2026; status: completed.
02
Drugs
ethinylestradiol + levonorgestreldoxycycline
03
Conditions
Incomplete Abortion (IA)retained placenta
Beyond the preview
Go deeper on IRCT20260516069413N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260516069413N1.